Home › Compare › MRUS vs NNN

MRUS vs NNN: Dividend Comparison 2026

MRUS yields 2.22% · NNN yields 5.66%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NNN wins by $2.5K in total portfolio value· pulled ahead in Year 7
10 years
MRUS
MRUS
● Live price
2.22%
Share price
$90.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$23.0K
Annual income
$256.54
Full MRUS calculator →
NNN
NNN REIT Inc.
● Live price
5.66%
Share price
$42.03
Annual div
$2.38
5Y div CAGR
8.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.5K
Annual income
$2,622.67
Full NNN calculator →

Portfolio growth — MRUS vs NNN

📍 NNN pulled ahead of the other in Year 7

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMRUSNNN
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MRUS + NNN cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
MRUS pays
NNN pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MRUS
Annual income on $10K today (after 15% tax)
$188.89/yr
After 10yr DRIP, annual income (after tax)
$218.06/yr
NNN
Annual income on $10K today (after 15% tax)
$481.32/yr
After 10yr DRIP, annual income (after tax)
$2,229.27/yr
At 15% tax rate, NNN beats the other by $2,011.21/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MRUS + NNN for your $10,000?

MRUS: 50%NNN: 50%
100% NNN50/50100% MRUS
Portfolio after 10yr
$24.2K
Annual income
$1,439.61/yr
Blended yield
5.94%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRUS right now

MRUS
Analyst Ratings
10
Buy
12
Hold
Consensus: Hold
Price Target
$97.00
+7.8% upside vs current
Range: $97.00 — $97.00
Altman Z
34.5
Piotroski
3/9
NNN
Analyst Ratings
10
Buy
15
Hold
4
Sell
Consensus: Hold
Price Target
$44.93
+6.9% upside vs current
Range: $43.00 — $48.50
Altman Z
1.1
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MRUS buys
0
NNN buys
2
PoliticianChamberTickerTypeAmountDate
Lisa McClain🏢 House$NNN▼ Sell$1,001 - $15,0002025-08-13
Lisa McClain🏢 House$NNN▲ Buy$1,001 - $15,0002025-06-17
Zoe Lofgren🏢 House$NNN▼ Sell$1,001 - $15,0002023-05-25
Ro Khanna🏢 House$NNN▼ Sell$1,001 - $15,0002022-01-20
Zoe Lofgren🏢 House$NNN▲ Buy$1,001 - $15,0002021-09-30
Zoe Lofgren🏢 House$NNN▼ Sell$1,001 - $15,0002020-03-23
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMRUSNNN
Forward yield2.22%5.66% ✓
Annual dividend / share$2.00$2.38 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%8.6% ✓
Portfolio after 10y$23.0K$25.5K ✓
Annual income after 10y$256.54$2,622.67 ✓
Total dividends collected$2.4K$13.7K ✓
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusHoldHold
Analyst price target$97.00 ✓$44.93

Year-by-year: MRUS vs NNN ($10,000, DRIP)

YearMRUS PortfolioMRUS Income/yrNNN PortfolioNNN Income/yrGap
1$10,922$222.22$10,735$614.96+$187.00 → MRUS
2$11,914$226.84$11,572$708.43+$342.00 → MRUS
3$12,979$231.24$12,531$819.53+$448.00 → MRUS
4$14,123$235.43$13,633$952.29+$490.00 → MRUS
5$15,351$239.43$14,909$1,111.84+$442.00 → MRUS
6$16,669$243.22$16,392$1,304.77+$277.00 → MRUS
7← crossover$18,082$246.82$18,129$1,539.52$47.00 → NNN
8$19,598$250.24$20,173$1,827.08$575.00 → NNN
9$21,224$253.47$22,597$2,181.81$1.4K → NNN
10$22,966$256.54$25,491$2,622.67$2.5K → NNN

MRUS vs NNN: Complete Analysis 2026

MRUS — Stock

Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

Full MRUS Calculator →

NNN — REIT

National Retail Properties invests primarily in high-quality retail properties subject generally to long-term, net leases. As of September 30, 2020, the company owned 3,114 properties in 48 states with a gross leasable area of approximately 32.4 million square feet and with a weighted average remaining lease term of 10.7 years.

Full NNN Calculator →
📬

Get this MRUS vs NNN comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MRUS vs SCHDMRUS vs JEPIMRUS vs OMRUS vs KOMRUS vs MAINMRUS vs ADCMRUS vs EPRTMRUS vs FCPT

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.